Ideaya Biosciences Inc
Ideaya Biosciences Inc (IDYA) Wheel Strategy
IDYA wheel strategy scan found 12 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 80.3%.
Read more
Running a IDYA wheel strategy lets you generate consistent premium income on Ideaya Biosciences Inc while setting your own entry and exit prices on the underlying. Ideaya Biosciences Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own IDYA, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best IDYA wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on IDYA, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable IDYA wheel from a losing one.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the IDYA wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your IDYA wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Dec 18, 2026 | 25.00 | $0.05 | $2.48 | -0.23 | 45 | 39% | 79.0% | 80.3% | 0 |
| Dec 18, 2026 | 27.50 | $0.10 | $2.50 | -0.29 | 45 | 39% | 66.4% | 73.7% | 0 |
| Dec 18, 2026 | 30.00 | $0.10 | $2.50 | -0.38 | 45 | 39% | 52.8% | 67.6% | 1 |
| Nov 20, 2026 | 30.00 | $0.05 | $0.78 | -0.32 | 17 | 39% | 58.8% | 55.5% | 114 |
| Jan 15, 2027 | 25.00 | $0.05 | $2.48 | -0.23 | 73 | 39% | 72.0% | 49.5% | 12 |
| Nov 20, 2026 | 27.50 | $0.05 | $0.58 | -0.19 | 17 | 39% | 78.7% | 44.9% | 0 |
| Jan 15, 2027 | 30.00 | $0.20 | $2.55 | -0.37 | 73 | 39% | 50.2% | 42.5% | 20 |
| Apr 16, 2027 | 20.00 | $0.05 | $2.48 | -0.15 | 164 | 39% | 77.3% | 27.5% | 9 |
| Apr 16, 2027 | 25.00 | $0.10 | $2.50 | -0.23 | 164 | 39% | 60.9% | 22.3% | 2 |
| Apr 16, 2027 | 27.50 | $0.50 | $2.70 | -0.28 | 164 | 39% | 53.0% | 21.9% | 50 |
As of Nov 5, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →